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Abstract
Background: Acute peritonitis developing in response to gram-negative bacterial infection is
known to act as a trigger for the development of acute lung injury which is often complicated by
the development of nosocomial pneumonia. We hypothesized that endotoxin-induced peritonitis
provokes recruitment of monocytes into the lungs, which amplifies lung inflammatory responses to
a second hit intra-alveolar challenge with endotoxin.
Methods: Serum and lavage cytokines as well as bronchoalveolar lavage fluid cells were analyzed
at different time points after intraperitoneal or intratracheal application of LPS.
Results: We observed that mice challenged with intraperitoneal endotoxin developed rapidly
increasing serum and bronchoalveolar lavage fluid (BALF) cytokine and chemokine levels (TNFα,
MIP-2, CCL2) and a nearly two-fold expansion of the alveolar macrophage population by 96 h, but
this was not associated with the development of neutrophilic alveolitis. In contrast, expansion of
the alveolar macrophage pool was not observed in CCR2-deficient mice and in wild-type mice
systemically pretreated with the anti-CD18 antibody GAME-46. An intentional two-fold expansion
of alveolar macrophage numbers by intratracheal CCL2 following intraperitoneal endotoxin did not
exacerbate the development of acute lung inflammation in response to intratracheal endotoxin
compared to mice challenged only with intratracheal endotoxin.
Conclusion: These data, taken together, show that intraperitoneal endotoxin triggers a CCR2-
dependent de novo recruitment of monocytes into the lungs of mice but this does not result in an
accentuation of neutrophilic lung inflammation. This finding represents a previously unrecognized
novel inflammatory component of lung inflammation that results from endotoxin-induced
peritonitis.
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Background
Overwhelming innate immune responses to systemic
inflammation contribute to the clinical manifestation of
sepsis and septic shock. Acute respiratory distress syn-
drome (ARDS) and multiorgan failure are frequent com-
plications of severe sepsis that contribute to the morbidity
and mortality of this critical illness [1]. The molecular
events eliciting sepsis-related complications such as acute
lung injury have only been partially defined. For example,
experimental animal models of endotoxin (lipopolysac-
charide, LPS) induced acute peritonitis have characterized
the kinetics of intraperitoneal LPS resorption and its rapid
appearance within the vascular compartment within min-
utes to hours [2]. In human studies, patients who develop
ARDS have highly elevated serum and alveolar cytokine
and chemokine levels that are associated with a massive
accumulation of neutrophils within the lungs, expanded
alveolar macrophage populations and increased lung
injury scores [3,4]. Key chemokines involved in this proc-
ess of lung leukocyte invasion include the main monocyte
chemoattractant CCL2 and the neutrophil chemoattract-
ants MIP-2, KC and MIP-1α [4,5].
Although expansion of alveolar macrophage populations
in septic ARDS patients is a well described phenomenon,
the underlying molecular events shaping this leukocytic
response are not known. In particular, it is unclear
whether such expanded alveolar macrophage pools in
septic ARDS patients are functionally relevant in terms of
aggravating lung inflammatory responses to secondary
pneumonia, which complicate the later phase of septic
ARDS. Previously published studies employing a two hit
model of initial intraperitoneal LPS challenge to trigger
sepsis-induced remote lung inflammatory responses fol-
lowed by a secondary intratracheal LPS challenge to
mimic the additional development of pneumonia have
not addressed changes in alveolar macrophage pool sizes
and related functional consequences [2]. Clearly, both
newly recruited alveolar monocytes and resident macro-
phages are potentially involved in the overall lung inflam-
matory response. We have recently demonstrated alveolar
accumulations of CD14-positive mononuclear phago-
cytes and elevated BAL fluid CCL2 levels together with an
expanded alveolar macrophage pool correlating with
increased lung injury scores in patients with sepsis related
ARDS [4]. In addition, we recently showed in an animal
model that intratracheal application of CCL2 plus LPS
synergistically induced acute lung inflammation, indicat-
ing that monocytes that are recruited into the lungs of
mice may both expand the alveolar macrophage pool and
aggravate LPS-induced neutrophilic alveolitis and lung
injury in mice [6]. Thus, an expansion of alveolar macro-
phage pool sizes may be observed in both septic ARDS
patients and in experimental animal models with ARDS-
like inflammatory phenotypes [4,6], and expanded alveo-
lar macrophage pools may be involved in remote lung
injury developing in response to systemic inflammation
[4,5]. Against this background, we hypothesized that LPS-
induced peritonitis effects alveolar macrophage pool sizes
by provoking the recruitment of circulating monocytes
into the lungs, thereby amplifying lung inflammatory
responses to a second hit intra-alveolar endotoxin chal-
lenge. We found that LPS-induced peritonitis was suffi-
cient to elicit a robust twofold expansion of the alveolar
Increased serum and bronchoalveolar lavage fluid TNFα,  MIP-2 and CCL2 levels in mice in response to intraperitoneal  endotoxin application Figure 1
Increased serum and bronchoalveolar lavage fluid 
TNFα, MIP-2 and CCL2 levels in mice in response to 
intraperitoneal endotoxin application. Mice were either 
left untreated (0 h time points) or received a single intraperi-
toneal endotoxin application (50 µg/mouse). At various time 
points thereafter, mice were sacrificed and serum (A) and 
BAL fluid (B) TNFα (black bars), MIP-2 (grey bars) and CCL2 
(white bars) levels were quantified by ELISA. The values are 
shown as mean ± SEM of 4–6 independent experiments. * 
indicates p < 0.01 versus respective control (0 h).
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macrophage pool without generating neutrophilic alveo-
litis. Using a two hit model of initial intraperitoneal plus
intratracheal LPS application to mimic peritonitis-
induced lung inflammation that is complicated by Gram-
negative pneumonia, we found-contrarily to our initial
hypothesis- that the observed alveolar macrophage expan-
sion did not result in an aggravation of the overall lung
inflammatory response to alveolar LPS challenge.
Materials and methods
Animals
BALB/c female mice (18–22 g) were purchased from
Charles River (Sulzfeld, Germany). CCR2-deficient mice
were generated on a mixed C57BL/6 × 129/Ola genetic
background by targeted disruption of the CCR2 gene, as
described previously [7]. The disrupted gene was back-
crossed for six generations to wild-type BALB/c mice. Par-
ent and offspring CCR2-/- mice on the BALB/c background
were bred under specific pathogen free (SPF) conditions.
Animals 8–12 weeks old were used for the described
experiments. Each treatment group consisted of at least 5
mice, unless indicated otherwise. This animal study was
approved by the local government committee.
Reagents
Lipopolysaccharide (E. coli, serotype O111:B4) was pur-
chased from Sigma (Deisenhofen, Germany). Murine
recombinant CCL2 (JE/MCP-1) was purchased from
Peprotech (Tebu, Offenbach, Germany). Function-block-
ing rat antimurine CD18 antibody (clone GAME-46) was
purchased from BD Biosciences (Heidelberg, Germany).
All reagents and antibodies were ascertained to be endo-
toxin-free by Limulus amoebocyte lysate (LAL) assay
(Chromogenix, Mölndal, Sweden).
Treatment protocols
Intratracheal applications of the various inflammatory
stimuli and recombinant proteins was done essentially as
described elsewhere [5,6,8-11]. Briefly, tracheas of anaes-
thetized mice were surgically exposed, and an Abbocath
catheter (Abbot, Wiesbaden, Germany) was inserted into
the trachea. Subsequently, indicated concentrations of
LPS or recombinant proteins (dissolved in total volumes
of approximately 80 µl saline/0.1% endotoxin-free
human serum albumin) were slowly instilled under stere-
omicroscopic control (Leica MS5, Wetzlar, Germany).
Subsequently, the skin was sutured and mice were
allowed to recover with free access to food and water.
Wild-type and CCR2-deficient mice (where indicated)
were sedated with ketamine and received intraperitoneal
(IP) injections of sterile LPS (50 µg/mouse) for various
time intervals (0 h, 3 h, 6 h, 24 h, 48 h, 72 h, 96 h, 120 h,
144 h). In a second set of experiments, mice received ini-
tial intraperitoneal LPS applications, and at various time
points thereafter, additional intratracheal (IT) applica-
tions of LPS (1 µg/mouse) to mimic the frequently
observed clinical complication of pneumonia developing
subsequent to the onset of septic ARDS that is associated
with peritonitis. In a third set of experiments, mice
received initial intraperitoneal LPS applications and 48 h
later, received a single intratracheal application of recom-
binant CCL2 (50 µg/mouse) to further increase alveolar
monocyte accumulations within the lung. At another 48 h
post CCL2 application (i.e., 96 h after initial IP LPS appli-
cation), mice were challenged intratracheally with LPS (1
µg/mouse) for 24 h. In a fourth set of experiments, mice
received intratracheal applications of both CCL2 (50 µg/
mouse) plus LPS (1 µg/mouse), according to recently pub-
lished protocols [6,8,9]. The dose of 1 µg LPS/mouse was
chosen to induce an easily detectable neutrophilic alveo-
litis in mice that also allows monitoring of changes in
magnitudes and durations of the neutrophilic responses
depending on the various experimental settings [11]. On
the other hand, to elicit a robust monocytic response, we
followed recently published experimental protocols and
Intraperitoneal endotoxin application elicits alveolar macro- phage expansion in mice Figure 2
Intraperitoneal endotoxin application elicits alveolar 
macrophage expansion in mice. Mice were either left 
untreated (0 h time point) or were challenged intraperito-
neally with a single dose of endotoxin (50 µg/mouse). At var-
ious time points post treatment, mice were sacrificed and 
subjected to bronchoalveolar lavage for determination of 
alveolar macrophage (black bars) and neutrophil (white bars) 
numbers, as indicated. Values are given as mean ± SEM of six 
mice per treatment group (96 h time point, n = 15). * indi-
cates p < 0.01 versus control (0 h), + indicates p < 0.01 ver-
sus 96 h time point.
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challenged mice intratracheally with 50 µg CCL2/mouse
(where indicated). This strong CCL2 challenge has been
described recently to establish a potent CCL2 chemokine
gradient and subsequent selective monocyte recruitment
towards the alveolar compartment [6,8,9]. For inhibition
experiments, mice received intravenous injections of func-
tion-blocking anti-CD18 antibody GAME-46 (100 µg/
mouse) 15 min prior to IP LPS application and every 24 h
post IP LPS application. In initial experiments, repeated
intraperitoneal GAME-46 antibody injections did not
show any overt side effects and were well tolerated by the
mice. Overall mortalities ranged below 10%.
Collection and analysis of blood samples and 
bronchoalveolar lavage
Mice were sacrificed and blood sample and bronchoalve-
olar lavage collection was done as recently outlined in
detail [6,8-10]. Briefly, mice were exposed to an overdose
of isofluoran (Abbott, Wiesbaden, Germany) and blood
was collected from the inferior vena cava. The bronchoal-
veolar lavage (BAL) fluid was obtained by cannulating the
trachea with a shortened 21 G needle attached to a 1-ml
insulin syringe, followed by repeated intratracheal instil-
lations of 0.5 ml aliquots of PBS (pH 7,2, supplemented
with 2 mM EDTA). Quantification of TNFα, MIP-2 and
CCL2 proteins in BAL fluid and serum samples was per-
formed using commercially available ELISA kits (lower
detection limits, 2 pg/ml), as recommended by the man-
ufacturer (R&D Systems, Wiesbaden, Germany). BAL cells
were counted with a hemocytometer and quantitation of
alveolar macrophages, alveolar recruited monocytes and
neutrophils was done on differential cell counts of Pap-
penheim-stained cytocentrifuge preparations using over-
all morphological criteria, including differences in cell
size and shape of nuclei and subsequent multiplication of
those values with the respective total BAL cell counts, as
recently described [10,11].
In vivo lung permeability assay
For evaluation of IP LPS-induced lung permeability, mice
received an intravenous injection of FITC-labeled human
albumin (1 mg/mouse in 100 µl PBS; Sigma, Deisen-
hofen, Germany) 1 hour before death, as recently
described [5,9]. Undiluted BAL fluid samples and serum
samples (diluted 1:10 and 1:100 in PBS, pH 7.4) were
placed in a 96-well microtiter plate and fluorescence
intensities were measured using a fluorescence spectrom-
eter (Bio-Tek FL 880 microplate fluorescence reader) oper-
ating at 488 nm absorbance and 525 ± 20 nm emission
wavelengths, respectively. The lung permeability index is
defined as the ratio of fluorescence signals of undiluted
BAL fluid samples to fluorescence signals of 1:10 diluted
serum samples.
Statistics
The study data are expressed as mean ± SEM. Significant
differences between controls and treatment groups of
serum and BAL fluid cytokine levels were calculated by
one-factor ANOVA with posthoc tests by Dunnet. Signifi-
cant differences in numbers of alveolar macrophages and
PMN were calculated by two-way ANOVA with post-hoc
tests using the Dunnet procedure. Differences were
assumed to be significant when P values were < 0.01.
Results and discussion
To evaluate the effect of systemic inflammation induced
by intraperitoneal LPS application on remote lung inflam-
matory responses, mice were challenged with a single
intraperitoneal LPS injection (50 µg/mouse) and changes
in both serum and bronchoalveolar lavage fluid cytokine/
chemokine profiles as well as BAL fluid cellular constitu-
ents were monitored at various time points thereafter. As
shown in Fig. 1A, serum TNFα, MIP-2 and CCL2 levels
dramatically (> 100-fold) increased in response to intra-
peritoneal application of LPS, peaking at 3 h and 6 h and
returning to near baseline levels by 48 h after treatment,
which is in agreement with previous reports [2,11]. At the
Alveolar macrophage expansion elicited in endotoxin- induced peritonitis is CCR2-dependent Figure 3
Alveolar macrophage expansion elicited in endo-
toxin-induced peritonitis is CCR2-dependent. Wild-
type mice or CCR2-deficient mice were either left untreated 
or received a single intraperitoneal LPS application (50 µg/
mouse) or wild-type mice were pretreated with function-
blocking anti-CD18 antibodies prior to and every 24 h post 
intraperitoneal LPS application, as indicated. At 96 h post-
treatment, mice were sacrificed and alveolar macrophages 
(black bars) and neutrophils (white bars) contained in bron-
choalveolar lavage were quantified. Values are given as mean 
± SEM of five mice per treatment group. * indicates p < 0.01 
compared to all other treatment groups.
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same time, MIP-2 and CCL2 but not TNFα levels were also
significantly increased in the BAL fluid compared to
untreated controls, albeit at much lower levels (Fig. 1B).
To evaluate, whether this increase in BAL fluid cytokines/
chemokines was due to increased lung vascular leakage in
response to intraperitoneal LPS treatment, mice received
FITC-labeled albumin shortly before intraperitoneal LPS
application, and FITC-albumin leakage into the alveolar
air space was monitored at 3 h and 6 h post-treatment.
However, we did not observe increased lung permeability
in the IP LPS treated mice, which indicates that cytokine/
chemokine leakage from the vascular to the alveolar com-
partment does not account for the elevated concentration
in BAL fluid in our model (IP LPS (3 h), 0.10 ± 0.02 AU,
IP LPS (6 h) 0.08 ± 0.01 AU, control, 0.12 ± 0.03 AU). This
observation is different from that of Qu and coworkers
who reported an induction of lung permeability in a rat
model of induced endotoxin tolerance provoked by
repeated intraperitoneal LPS applications. Qu et al.
employed high-dose LPS injections amounting to 6 mg/kg
body weight, corresponding to ~1,200 µg LPS/rat,
whereas we used a single medium dose LPS application
amounting to 2,5 mg/kg body weight, corresponding to
~50 µg LPS/mouse [12]. Differences in lung permeability
changes observed between these two studies are most
probably due to differences in experimental settings and
animal models employed. In addition, since systemic LPS
is known to rapidly sequester circulating leukocytes
within lung capillaries and interstitium, such leukocytes
likely prime alveolar epithelial cells to release chemokines
and other proteins into the alveolar air space in a polar-
ized manner, which may represent an alternative possibil-
ity to increase BAL fluid protein contents in the absence of
increased lung permeability [13]. The latter scenario is
supported by the observation that systemic anti-CD18
antibody application to block leukocyte-endothelial cell
interactions was effective in lowering BAL fluid proin-
flammatory cytokine levels in acute lung inflammation
[5].
Evaluation of BAL fluid cellular constituents revealed that
intraperitoneal LPS application provoked a delayed and
robust two-fold expansion of the alveolar macrophage
population by 96 h post-treatment (Fig. 2). However,
under the chosen experimental conditions (50 µg LPS/
mouse intraperitoneally), we observed no neutrophil
recruitment into the alveolar compartment. In an effort to
dissect the molecular pathways mediating this novel and
unexpected lung inflammatory response to intraperito-
neal LPS application, mice lacking the CCL2 receptor,
CCR2 were challenged intraperitoneally with LPS. In con-
trast to wild-type mice, CCR2-deficient mice did not
respond with an alveolar macrophage expansion upon
intraperitoneal LPS application, which indicates that lung
inflammatory monocyte trafficking observed in IP LPS
Alveolar macrophage expansion elicited by intraperitoneal  LPS application does not enhance neutrophilic alveolitis and  cytokine release in response to subsequent intratracheal LPS  application Figure 4
Alveolar macrophage expansion elicited by intraperi-
toneal LPS application does not enhance neutrophilic 
alveolitis and cytokine release in response to subse-
quent intratracheal LPS application. Mice were either 
left untreated or received an intraperitoneal LPS application 
(50 µg/mouse) for either 96 h or 144 h or intratracheal LPS 
alone (1 µg/mouse) for 24 h or combinations of intraperito-
neal LPS followed by intratracheal LPS application, as indi-
cated. Subsequently, bronchoalveolar lavage fluid neutrophil 
numbers (A) and BAL fluid (B) TNFα (black bars), MIP-2 
(grey bars) and CCL2 (white bars) levels were quantified by 
ELISA. Values are given as mean ± SEM of at least five mice 
per treatment group. * indicates p < 0.01 versus control.
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challenged wild-type mice is dependent on CCL2 interact-
ing with its receptor, CCR2 as underlying mechanism (Fig.
3) [6,9]. Moreover, since inflammatory monocyte traffick-
ing to the lung is known to depend on engagement of β2
integrins [9], wild-type mice received function-blocking
anti-CD18 antibodies to block β2 integrin-dependent
molecular pathways prior to intraperitoneal LPS applica-
tion. Importantly, this experimental manoeuvre com-
pletely inhibited the alveolar macrophage expansion in
response to intraperitoneal LPS (Fig. 3). Although alveolar
macrophage expansion has been described in septic ARDS
patients [3,4], the currently presented data are novel and
expand previous observations by demonstrating that the
process of intra-alveolar macrophage expansion in
response to remote (ie, intraperitoneal) LPS application
involves a β2 integrin-dependent and CCL2-CCR2-medi-
ated de novo recruitment of peripheral blood monocytes
into the alveolar air space. In addition or alternatively to
putative alveolar macrophage proliferation discussed for
inflamed lungs [14], de novo recruitment of monocytes to
the alveolar space may thus represent a robust mechanism
to increase the alveolar macrophage pool.
We and others recently demonstrated that alveolar macro-
phages are essential to the initiation of LPS-induced acute
lung inflammation [10,15]. Liposomal clodronate-
induced alveolar macrophage depletion prior to intratra-
cheal LPS application largely abrogated LPS-induced
cytokine liberation and neutrophilic alveolitis in mice
[9,13]. Against this background, we further hypothesized
that increased alveolar macrophage numbers observed in
the lungs of mice pretreated intraperitoneally with LPS
strongly amplify the alveolar inflammatory response to an
additional alveolar LPS challenge, reflecting the fre-
quently observed clinical complication of developing
pneumonia in septic ARDS patients. Again, intraperito-
neal LPS application alone did not provoke any substan-
tial intra-alveolar neutrophil accumulation, irrespective of
the time point investigated, whereas intratracheal LPS
application alone induced a strong alveolar neutrophil
recruitment by 24 h post-treatment (Fig. 4). However,
when mice were challenged intratracheally with LPS at the
time point where maximum alveolar macrophage accu-
mulation triggered by intraperitoneal LPS application was
observed (ie, at 96 h post intraperitoneal LPS treatment,
see Fig. 2), the developing neutrophilic alveolitis and
associated BAL fluid cytokine/chemokine levels was in the
same order of magnitude as observed in those mice receiv-
ing only intratracheal LPS applications for 24 h in the
absence of intraperitoneal LPS pre-challenge (Fig. 4A, B).
Similar observations regarding the extent of neutrophilic
alveolitis and BAL fluid cytokine/chemokine levels were
made when mice received intratracheal LPS applications
at 144 h post intraperitoneal LPS challenge, when alveolar
macrophage numbers had already returned to near base-
Monocytes recruited into the lungs in response to intraperi- toneal LPS do not enhance but rather decrease neutrophilic  alveolitis in mice challenged with CCL2 plus LPS Figure 5
Monocytes recruited into the lungs in response to 
intraperitoneal LPS do not enhance but rather 
decrease neutrophilic alveolitis in mice challenged 
with CCL2 plus LPS. (A) Treatment groups of experi-
ments shown in (B). Mice were either left untreated (bar 1) 
or received LPS intraperitoneally for 96 h (bar 2) or received 
intratracheal LPS applications alone for 24 h (bar 3) (1 µg/
mouse). In addition, groups of mice received either com-
bined intraperitoneal LPS applications (50 µg/mouse) and 96 
h later, an intratracheal LPS application for 24 h (1 µg/mouse) 
(bar 4) or combined intratracheal applications of CCL2 for 
48 h (50 µg/mouse) plus LPS for 24 h (1 µg/mouse) (bar 6) or 
were pretreated with intraperitoneal LPS for 48 h, followed 
by instillation of CCL2 (50 µg/mouse) for another 48 h fol-
lowed by an intratracheal LPS application for 24 h (bar 5). 
Subsequently, mice were sacrificed and total numbers of 
alveolar recruited neutrophils were calculated. Values are 
given as mean ± SEM of at least five mice per treatment 
group. * indicates p < 0.01 versus control, + indicates p < 
0.01 compared to all other treatment groups.
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line values (Fig. 4, and see Fig. 2 for comparison). Collec-
tively, the data show that robust increases in alveolar
macrophage numbers developing in mice at 96 h post sys-
temic LPS application did not increase the release of
proinflammatory mediators within the alveolar air space
nor aggravated the neutrophilic alveolitis provoked by a
secondary intra-alveolar LPS challenge.
Intra-alveolar deposition of high doses of recombinant
CCL2 (50 µg/mouse) employed to trigger a maximal cel-
lular response has recently been shown to recruit substan-
tial numbers of circulating monocytes into the lungs of
mice [8,9]. In the current study, we used this approach to
further expand the alveolar macrophage pool over that
occurring in response to intraperitoneal LPS application
alone (data not shown) and questioned, whether the
cumulative alveolar macrophage expansion resulting
from both initial intraperitoneal LPS plus additional
intratracheal CCL2 instillation would ultimately increase
the alveolar neutrophilic response upon subsequent
intratracheal LPS application. As shown in Fig. 5, mice
treated with both intraperitoneal LPS plus intratracheal
CCL2 applications developed a neutrophilic alveolitis
upon secondary intratracheal LPS similar to that observed
in mice pretreated with intraperitoneal LPS plus second-
ary intratracheal LPS application 96 h later (Fig. 5, bar 5
vs. 4). In contrast, when untreated mice received an intrat-
racheal CCL2 instillation for 48 h followed by an intratra-
cheal LPS application for another 24 h, neutrophilic
alveolitis was significantly increased, consistent with
recently published reports (bar 6) [5,6]. Of note, the dif-
ferences in developing neutrophilic alveolitis were not
due to different numbers of newly recruited alveolar
monocytes between these two treatment groups (IP LPS
plus IT CCL2 plus IT LPS (bar 5), 191,500 ± 20,000
monocytes versus IT CCL2 plus IT LPS (bar 6), 189,500 ±
20,000 monocytes).
Thus, in sharp contrast to what we initially expected, these
data lend support to the concept that monocytes recruited
from inflamed vascular compartments into the lungs
apparently do not aggravate neutrophilic alveolitis in
response to secondary intra-alveolar LPS challenge,
whereas alveolar monocytes recruited from non-inflamed
vascular compartments significantly contribute to neu-
trophilic alveolitis upon intratracheal LPS application, the
latter being consistent with recent reports [5,6].
One possible explanation why the increased lung mono-
cyte traffic leading to an expansion of the alveolar macro-
phage pool in response to intraperitoneal LPS did not
aggravate the neutrophilic alveolitis upon subsequent
intratracheal LPS application may involve changes in TLR
expression profiles on circulating monocytes pre-exposed
to systemic LPS (absorbed from the peritoneal cavity)
prior to being recruited into the lungs [16,17]. Such
monocytes might exhibit a reduced potential to mount
proinflammatory responses within the alveolar air space
upon secondary challenge with locally applied LPS. Such
attenuation of alveolar inflammatory responses might
affect the lung host defense under conditions of systemic
inflammation. This hypothesis of a dysregulated TLR gene
expression pattern in LPS "pre-exposed" circulating
monocytes is currently being addressed in our lab in more
detail.
Conclusion
Together, the presented data for the first time show that
intraperitoneal LPS application in mice elicits a remote
lung inflammatory response reflected by a CCR2-depend-
ent and β2 integrin mediated robust expansion of the
alveolar macrophage pool. However, no evidence was
found to demonstrate that the observed monocyte immi-
gration and resulting alveolar macrophage expansion sub-
sequent to systemic inflammation leads to an aggravated
neutrophilic alveolitis developing in response to a "sec-
ond hit" alveolar LPS application. This finding is opposite
to the enhanced neutrophilic alveolitis observed in mice
where monocytes were recruited from a non-inflamed
vascular compartment to the lungs (ie, in response to
intratracheal CCL2 plus LPS) to expand alveolar macro-
phage numbers. These data may contribute to a better
understanding of the inflammatory capacity of mononu-
clear phagocytes in the lungs of septic ARDS patients.
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